Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Authors: Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L. Daikos, Minggui Wang, Julián Torre‐Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, R. Jiménez-Rodríguez, Lu Liang, Gang Chen, O. V. Pyptіuk, Firdevs Aksoy, Halley Rogers, Michele Wible, Francis F. Arhin, Alison Luckey, Joanne L. Leaney, Rienk Pypstra, Joseph W. Chow, Marc Bonten, Jesús Rodríguez‐Baño, Christine Lammens, Herman Goossens, Surbhi Malhotra‐Kumar - The Lancet 2024 cited by 102